Century Therapeutics SVP sells 292 shares at $0.586 for taxes
Century Therapeutics (IPSC) insider transaction: The company’s SVP Finance & Operations reported selling 292 shares of common stock at $0.586 on November 3, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Century Therapeutics (IPSC) insider transaction: The company’s SVP Finance & Operations reported selling 292 shares of common stock at $0.586 on November 3, 2025.
The filing states these sales were executed to satisfy tax withholding obligations tied to the vesting of restricted stock units and were automatic, not at the reporting person’s discretion. Following the transaction, the insider beneficially owns 405,131 shares, held directly.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 292 | $0.586 | $171.11 |
Footnotes (1)
- F1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Century Therapeutics (IPSC) disclose in this Form 4?
Who executed the transaction at Century Therapeutics (IPSC)?
When did the IPSC insider transaction occur?
AI-generated analysis. How Rhea-AI works. Not financial advice.